Kurs
+3,36%
Kurs
+3,36%
Open
81,50
High
82,00
Low
70,00
Close
77,00
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
17,1 MNOK
Likviditet
17,1 MNOK
Rel. mcap
2,77%
Antal aktier
227 285
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-10-23 | 08:00 | Kvartalsrapport 2025-Q3 |
| 2025-07-10 | 08:00 | Kvartalsrapport 2025-Q2 |
| 2025-05-07 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-05-06 | N/A | Årsstämma |
| 2025-02-12 | 08:30 | Bokslutskommuniké 2024 |
| 2024-10-31 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-29 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-30 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-30 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2024-04-29 | - | Årsstämma |
| 2024-02-09 | - | Bokslutskommuniké 2023 |
| 2023-10-26 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-24 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2023-05-04 | - | Årsstämma |
| 2023-02-16 | - | Bokslutskommuniké 2022 |
| 2022-10-27 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-25 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-19 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2022-05-18 | - | Årsstämma |
| 2022-04-28 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-17 | - | Bokslutskommuniké 2021 |
| 2021-10-21 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-25 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-05 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2021-05-04 | - | Årsstämma |
| 2021-04-16 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-10-29 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-21 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-15 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2020-05-14 | - | Årsstämma |
| 2020-04-24 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-11-21 | - | Extra Bolagsstämma 2019 |
| 2019-05-10 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-07-13 | - | Extra Bolagsstämma 2018 |
| 2018-06-13 | - | X-dag ordinarie utdelning GENT 0.00 NOK |
| 2018-02-27 | - | Bokslutskommuniké 2017 |
| 2017-06-06 | - | Årsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2020-08-21 08:00:00
Moss, 21.08.20 Gentian Diagnostics AS announces its results for the second quarter and first half of 2020. The highlights include: * Record sales revenues of MNOK 16.6 in 2Q20, up from MNOK 10.2 in 2Q19 * Sales growth in 2Q20 of 64 % is especially based on Cystatin C sales in Asia. Sales in the quarter grew by 44 % YoY on a currency neutral basis * Successful release of fPELA® turbo, which is marketed by our partner BÜHLMANN * Gentian awarded up to MNOK 8.0 in funding to support the development of a high-throughput SARS-CoV-2 antibody test * New scientific publications propose calprotectin as a promising biomarker for the management of COVID-19 patients, which represents a new opportunity for our GCAL® assay Please find the report and results presentation enclosed. The documents will also be made available on www.gentian.no. For further information, please contact: Hilja Ibert CEO, Gentian Diagnostics E-mail: hilja.ibert@gentian.no Cell Phone: +47 919 05 242 Njaal Kind CFO, Gentian Diagnostics E-mail: njaal.kind@gentian.no Cell Phone. +47 919 06 525